Vasowatch

Vasowatch is a medtech startup developing a non-invasive digital biomarker that predicts postpartum hemorrhage (PPH) before delivery, alerting clinicians to unknown hemorrhage risk during labor. The technology streams maternal heart rate data to detect exhaustion of the uterine muscle — the leading cause of hemorrhage — enabling prompt treatment that could avert up to 60% of hemorrhage incidents and save an estimated $1B in obstetrics costs annually. Founded in May 2021 by University of Pennsylvania faculty members Christine Rohan (CEO), Stefanie Modri (Co-Founder), and James Weimer (Co-Founder), Vasowatch is a Penn Center of Innovation Ventures portfolio company and 2023 mHUB MedTech Accelerator graduate based in Philadelphia.